Therapy Areas: Inflammatory Diseases
Soligenix announces appointment of Jonathan Guarino as SVP and CFO
11 September 2019 -

Biopharmaceutical company Soligenix Inc (Nasdaq: SNGX) disclosed on Wednesday that Jonathan Guarino has been appointed as the company's senior vice president and chief financial officer.

The company said Guarino has a proven track record and expertise in corporate financial operations, partnerships, as well as growth financings. Including the life sciences industry, Guarino has more than two decades of diverse experience in financial and strategic management of emerging growth and commercial companies.

Guarino most recently served as corporate controller for New Jersey-based public biotechnology company Hepion Pharmaceuticals Inc.

Before that, he worked as controller and senior manager of technical accounting for Suite K Value Added Services LLC and Covance Inc.

Earlier in his career, Guarinoe held accounting and finance positions of increasing importance with companies such as PricewaterhouseCoopers LLP, BlackRock Inc and Barnes & Noble Inc.

Soligenix is focused on developing and commercialising products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma and its first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, along with proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterised by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).